New osteoarthritis drug Vimovo is now available in nine global markets and it generated second-quarter revenue of $6.3 million — more than double Vimovo’s sales in the first quarter of this year. But Chapel Hill, North Carolina-based Pozen (NASDAQ:POZN) believes that sales for the drug that it developed with drug partner AstraZeneca (NYSE:AZN) are not […]
North Carolina pharmaceutical company Pozen (NASDAQ:POZN) has named an AstraZeneca (NYSE:AZN) veteran to its board of directors, a key move as the company prepares to take a product to market on its own for the first time. Martin Nicklasson‘s experience spans both large and small pharmaceutical companies. At AstraZeneca, Nicklasson held various executive positions from […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
North Carolina pharmaceutical company Pozen (NASDAQ:POZN) and drug partner AstraZeneca (NYSE:AZN) are taking legal action to block a generic competitor to osteoarthritis drug Vimovo. The companies have filed a patent infringement lawsuit in U.S. District Court for the District of New Jersey against India-based generics company Dr. Reddy’s Laboratories (NYSE:RDY). Dr. Reddy’s notified both companies […]
Generic competition to Pozen’s (NASDAQ:POZN) migraine drug Treximet will be held at bay for now. A judge in the U.S. District Court for the Eastern District of Texas has granted a preliminary injunction that orders Par Pharmaceutical (NYSE:PRX) not to make or sell a generic version of Treximet, which is sold in the United States […]
The migraine drug developed by pharmaceutical company Pozen now has the opportunity for commercialization in parts of Latin America under a new licensing deal inked with a Johnson & Johnson subsidiary. Chapel Hill, North Carolina-based Pozen (NASDAQ:POZN) has already commercialized its compound MT 400 under the name Treximet, which is marketed through partner GlaxoSmithKline (NYSE:GSK). […]
Looming patent expiration on the migraine drug Treximet has led pharmaceutical company Pozen to take further legal action to fend off generic competition. Chapel Hill, North Carolina-based Pozen (NASDAQ:POZN) said Tuesday it has filed a preliminary injunction to prevent Par Pharmaceuticals from launching a Treximet generic. Pozen made the filing in the U.S. District Court […]
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
AstraZeneca's $25 million milestone payment to Pozen helped the Chapel Hill, North Carolina-based pharmaceutical company swing to a fourth-quarter profit of $18.4 million.
Pharmaceutical rep visits to doctors' offices will become a thing of the past as the industry adopts social media tools to market its products. Chapel Hill, North Carolina, company Pozen will be using a mainly digital marketing strategy when it takes its latest drug to market.